← Eichor
Condition: Other Solid Tumors Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Other Solid Tumors

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Phase 1/Phase 2 · 27 location(s) · Institut de Recherches Internationales Servier · NCT05786924A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harbor
Phase 2 · 31 location(s) · Allist Pharmaceuticals, Inc. · NCT06008288A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
Phase 1 · 15 location(s) · OnCusp Therapeutics, Inc. · NCT06234423Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusi
Phase N/A · 76 location(s) · Bayer · NCT04142437Multicohort Trial of Different Schemes of PM14 in Monotherapy and in Combination with Radiotherapy in Soft Tissue Sarcom
Phase 1/Phase 2 · 4 location(s) · Grupo Espanol de Investigacion en Sarcomas · NCT05146440Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy
Phase N/A · 1 location(s) · University of Erlangen-Nürnberg Medical School · NCT04892849A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell C
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06006169A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
Phase 1 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06493864A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Canc
Phase 1 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06500052A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With
Phase 1 · 1 location(s) · Providence Health & Services · NCT06719362Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
Phase 1/Phase 2 · 11 location(s) · Vironexis Biotherapeutics Inc. · NCT07192432A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
Phase 2 · 7 location(s) · Nanjing Leads Biolabs Co.,Ltd · NCT07331155Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastri
Phase 2 · 1 location(s) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · NCT06947291A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
Phase 1/Phase 2 · 4 location(s) · OncoResponse, Inc. · NCT06090266Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors
Phase 1/Phase 2 · 2 location(s) · Princess Maxima Center for Pediatric Oncology · NCT04925609AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
Phase 1 · 22 location(s) · Amgen · NCT07403721A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor
Phase 1/Phase 2 · 1 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT07140393A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced So
Phase 1 · 30 location(s) · Coherus Oncology, Inc. · NCT06657144A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Soli
Phase 1 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT07232524Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
Phase 1/Phase 2 · 87 location(s) · Betta Pharmaceuticals Co., Ltd. · NCT04930432CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With
Phase 2 · 1 location(s) · Northwestern University · NCT05733000A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumor
Phase 2 · 1 location(s) · Minghui Pharmaceutical (Hangzhou) Ltd · NCT07130383BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Phase 1 · 63 location(s) · BeOne Medicines · NCT06120283HEC169096 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Sunshine Lake Pharma Co., Ltd. · NCT05451602Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Phase 1/Phase 2 · 47 location(s) · Synthekine · NCT05098132A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Ac
Phase 1/Phase 2 · 74 location(s) · Nuvalent Inc. · NCT05384626A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Phase 1 · 25 location(s) · Arcus Biosciences, Inc. · NCT05536141Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA
Phase 1 · 23 location(s) · National Cancer Institute (NCI) · NCT05687110Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Phase 1 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT03454035A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Risen (Suzhou) Pharma Tech Co., Ltd. · NCT06208410
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.